Overall, our study supports the relevance of using GC-antagonist drugs as secondary therapies alongside SMN-dependent treatments for targeting both neuromuscular and metabolic pathologies in SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.